Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
NOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer
Chenfei Huang, Shhyam Moorthy, Qiuli Li, Kazi M. Ahmed, Kalil Saab, Defeng Deng, Jiping Wang, Xiayu Rao, Jiexin Zhang, Yuanxin Xi, Jing Wang, Zhiyi Liu, Noriaki Tanaka, David A. Wheeler, Eve Shinbrot, Rami Saade, Curtis R. Pickering, Tong-Xin Xie, Adel K. El-Naggar, Abdullah A. Osman, Kunal Rai, Patrick A. Zweidler-McKay, John V. Heymach, Lauren A. Byers, Faye M. Johnson, Vlad C. Sandulache, Jeffrey N. Myers, Pedram Yadollahi, Mitchell J. Frederick
Chenfei Huang, Shhyam Moorthy, Qiuli Li, Kazi M. Ahmed, Kalil Saab, Defeng Deng, Jiping Wang, Xiayu Rao, Jiexin Zhang, Yuanxin Xi, Jing Wang, Zhiyi Liu, Noriaki Tanaka, David A. Wheeler, Eve Shinbrot, Rami Saade, Curtis R. Pickering, Tong-Xin Xie, Adel K. El-Naggar, Abdullah A. Osman, Kunal Rai, Patrick A. Zweidler-McKay, John V. Heymach, Lauren A. Byers, Faye M. Johnson, Vlad C. Sandulache, Jeffrey N. Myers, Pedram Yadollahi, Mitchell J. Frederick
View: Text | PDF
Research Article Cell biology Oncology

NOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer

  • Text
  • PDF
Abstract

Inactivating NOTCH1 mutations in head and neck squamous cell carcinoma (HNSCC) were described over a decade ago, suggesting a tumor suppressor function — unlike its oncogenic role in other tumors. Today, much debate persists regarding a putative oncogenic role in HNSCC as well, with reports that NOTCH1 signaling drives tumor growth and a cancer stem cell (CSC) phenotype. In this work, comprehensive experiments unequivocally demonstrate that NOTCH1 is a tumor suppressor in HNSCC regardless of mutation or activation status and that it reduces CSC frequency. We developed a signature of NOTCH1 activation showing the pathway is associated with very early differentiation, an altered tumor microenvironment, and better prognosis. Clarifying whether NOTCH1 occasionally functions as an oncogenic driver in HNSCC is crucial to prognosis and personalized therapy. The results presented unify the field, reconcile conflicting data, and provide critical insights into the biological and clinical significance of NOTCH1, with broader implications in other squamous carcinomas with NOTCH1 mutations.

Authors

Chenfei Huang, Shhyam Moorthy, Qiuli Li, Kazi M. Ahmed, Kalil Saab, Defeng Deng, Jiping Wang, Xiayu Rao, Jiexin Zhang, Yuanxin Xi, Jing Wang, Zhiyi Liu, Noriaki Tanaka, David A. Wheeler, Eve Shinbrot, Rami Saade, Curtis R. Pickering, Tong-Xin Xie, Adel K. El-Naggar, Abdullah A. Osman, Kunal Rai, Patrick A. Zweidler-McKay, John V. Heymach, Lauren A. Byers, Faye M. Johnson, Vlad C. Sandulache, Jeffrey N. Myers, Pedram Yadollahi, Mitchell J. Frederick

×

Figure 3

The activation of NOTCH1 signaling through multiple experimental approaches consistently downregulates oncogenic drivers and modulates adhesion or other markers of early differentiation.

Options: View larger image (or click on image) Download as PowerPoint
The activation of NOTCH1 signaling through multiple experimental approac...
(A) Growth for 5 days on JAG1 significantly inhibited RNA expression of the basal cell marker genes ITGA1, ITGA3, ITGA6, LAMC1, and LAMC2 in 2 NOTCH1-WT cell lines, PJ34 and 183, while stimulating expression of the suprabasal maker genes KRT4 and KRT13. (B) Ectopic expression of cDNA encoding cl-NOTCH1 decreased expression of ITGA3, LAMC2, AXL, and α-catulin at 3 days and 5 days after infection in a NOTCH1-WT cell (PJ34) and in a NOTCH1-mutant cell (HN31). (C) AXL and α-catulin protein levels decline in NOTCH1-WT (PJ34) tumor cells grown on JAG1 (3 days) and in 3 different NOTCH1-mutant cell lines (HN31, UMSCC22A, UMSCC47) when expression of WT full-length NOTCH1 receptors (NFL1) is restored and then grown on JAG1 ligand for 3 days. Cells were also infected with empty vector (MigR1) and/or grown on control Fc protein. (D) PJ34 with CRISPR-mediated NOTCH1 KO were further engineered to express a DOX-inducible cl-NOTCH cDNA (PJ34-iICN1) whose expression was titrated after 72 hours of treatment with different doses of DOX, to achieve protein levels equivalent to parental PJ34 stimulated with JAG1 for 16 hours. (E) ICN1 induction with 1000 ng/mL DOX caused massive cell shrinkage and formation of loosely attached tumor spheroids. Scale bars: 100 μm. (F) Venn diagram illustrates overlap of genes in PJ34 significantly upregulated (FDR < 0.1, |fold change| ≥ 1.25) by growth on JAG1 or after 24 hours of iICN1 induction, and genes specifically bound in the promoter or gene body regions by iICN1 after ChIP-seq experiments. (G) Venn diagram illustrates overlap of genes in PJ34 significantly downregulated (FDR < 0.1, |fold change| ≥ 1.25) by growth on JAG1 or after 24 hours of iICN1 induction, and genes specifically bound in the promoter or gene body regions by iICN1 after ChIP-seq experiments.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts